Dalby, Sweden

Eva Erlandsson

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 104(Granted Patents)


Company Filing History:


Years Active: 2006-2009

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Eva Erlandsson: Innovator in Cancer Treatment

Introduction

Eva Erlandsson is a notable inventor based in Dalby, Sweden. She has made significant contributions to the field of cancer treatment through her innovative research and development. With a total of two patents to her name, her work focuses on advanced therapeutic methods that utilize bacterial superantigens.

Latest Patents

Eva's latest patents include groundbreaking methods for treating subjects with cancer. One patent details the administration of a conjugate between a variant staphylococcal enterotoxin E superantigen and an antibody that binds to the 5T4 antigen. This invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. The bacterial superantigen has been modified to decrease seroreactivity while retaining its superantigen activity. Another patent focuses on engineered superantigens for human therapy, emphasizing similar compositions and methods of use.

Career Highlights

Eva Erlandsson is associated with Active Biotech AB, where she continues to advance her research in cancer therapies. Her work is characterized by a commitment to improving treatment options for patients suffering from cancer.

Collaborations

Eva collaborates with esteemed colleagues such as Goran Forsberg and Per Antonsson, contributing to a dynamic research environment that fosters innovation.

Conclusion

Eva Erlandsson's contributions to cancer treatment through her innovative patents highlight her role as a leading inventor in the field. Her work continues to pave the way for new therapeutic approaches that could significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…